Pharma BD Deal Intelligence
Hectorol delivered a strong initial ramp and diversified Genzyme's renal franchise, but a 2011 Medicare reimbursement shift and 2014 patent expiry capped it as a durable niche product rather than the growth engine originally priced in.
Full analysis, sources & comparables →Genzyme CEO Henri Termeer: 'The addition of the Bone Care organization and the Hectorol brand will solidify and strengthen our growing renal business, while…
Genzyme CEO Henri Termeer said the deal would 'solidify and strengthen our growing renal business' by pairing Hectorol with the existing Renagel phosphate…
Stanford Group analyst Dallas Webb called the acquisition 'a very good fit for Genzyme' and 'a very good strategic move,' projecting combined sales-force…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Genzyme completes $600M cash acquisition of Bone Care; gains Hectorol (doxercalciferol) for renal/secondary hyperparathyroidism.
Hectorol delivered a strong initial ramp and diversified Genzyme's renal franchise, but a 2011 Medicare reimbursement shift and 2014 patent expiry capped it as a durable niche product rather than the growth engine originally priced in.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme Corporation / Bone Care International, Inc. (this deal) | 2005 | $600M | 61 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Genzyme Corporation / Biomatrix Inc. | 2000 | $700M | 65 |
| Genzyme Corporation / Novazyme Pharmaceuticals Inc. | 2001 | $138M | 54 |
| Genzyme Corporation / Verigen AG | 2005 | $50M | 29 |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
← Browse all deals · How we score deals
More: 2005 deals · Genzyme Corporation deals · Nephrology deals